Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Silexion Therapeutics ( (SLXN) ) has provided an announcement.
On December 2, 2025, Silexion Therapeutics announced it received positive feedback from the German Federal Institute for Drugs and Medical Devices (BfArM) regarding the design of its Phase 2/3 clinical trial for SIL204, a treatment for pancreatic cancer. This feedback is a significant milestone, providing regulatory clarity and supporting the company’s trajectory towards initiating the trial in the first half of 2026, pending regulatory approvals in Israel and Germany. The company is actively preparing for the trial launch, including manufacturing readiness and clinical site preparations.
The most recent analyst rating on (SLXN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers, particularly targeting unsatisfactorily treated solid tumor cancers with the mutated KRAS oncogene. The company is dedicated to advancing innovative treatments in oncology, with its lead product candidate being SIL204 for locally advanced pancreatic cancer.
Average Trading Volume: 489,382
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.63M
For a thorough assessment of SLXN stock, go to TipRanks’ Stock Analysis page.